Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd (OP: DSKYF )

28.22 UNCHANGED
Streaming Delayed Price Updated: 9:49 AM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 28.22
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 28.22
Today's Range 28.22 - 28.22
52wk Range 23.45 - 37.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. 
Via Benzinga

Performance

YTD
+7.22%
+7.22%
1 Month
-12.93%
-12.93%
3 Month
-5.02%
-5.02%
6 Month
+8.41%
+8.41%
1 Year
-19.62%
-19.62%

More News

Read More
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
Via Benzinga
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Via Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Via Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 6
Via Benzinga
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
Via Benzinga
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.